ETM
MED icon

Euclidean Technologies Management’s Medifast MED Stock Holding History

Euclidean Technologies Management’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,000
Closed -$3.6M – 99
2021
Q1 		$3.6M Hold
17,000
– – 3.13% 1
2020
Q4 		$3.34M Hold
17,000
– – 3.51% 1
2020
Q3 		$2.8M Hold
17,000
– – 3.52% 1
2020
Q2 		$2.36M Buy
+17,000
New +$1.56M 3.31% 1

Other funds holding MED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Euclidean Technologies Management's MED Position: Q2 2021 in Review

Euclidean Technologies Management sold out of Medifast (MED) in Q2 2021, closing a stake of 17,000 shares — an estimated $3.6M sold.

Euclidean Technologies Management first reported a position in MED in Q2 2020 and held it in 4 quarters. The position peaked at $3.6M in Q1 2021. 301 funds tracked by Wall St. Rank hold MED as of Q2 2021.

  • Euclidean Technologies Management reported no remaining Medifast position as of Q2 2021 after selling out during the quarter.
  • Euclidean Technologies Management sold 17,000 Medifast shares in Q2 2021, an estimated $3.6M.
  • Euclidean Technologies Management first reported a position in Medifast in Q2 2020 and held it in 4 quarters.
  • Euclidean Technologies Management's Medifast position peaked at $3.6M in Q1 2021.
  • 301 funds tracked by Wall St. Rank held Medifast as of Q2 2021.

Based on Euclidean Technologies Management's 13F filing for Q2 2021, filed 5 Aug 2021.